ViraCyte

ViraCyte is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe life threatening infections. ViraCyte’s current products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT). ViraCyte’s lead T cell products are in Phase 1 and Phase 2 clinical trials, with effectiveness rates of greater than 90% in patients who have failed conventional therapy.  

 

Focus area
Infectious Diseases & Vaccines
Graduation date
02/28/2018
Commencement date
02/01/2016